Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical Stock Down 3.1 %
Shares of NASDAQ:CLSD opened at $1.54 on Tuesday. The company has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.71. Clearside Biomedical has a 12 month low of $1.26 and a 12 month high of $7.73.
Clearside Biomedical (NASDAQ:CLSD - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Clearside Biomedical had a negative net margin of 5.54% and a negative return on equity of 5.60%. During the same period in the prior year, the business earned ($0.11) earnings per share. Research analysts expect that Clearside Biomedical will post -0.36 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities analysts have recently commented on the company. StockNews.com upgraded Clearside Biomedical from a "hold" rating to a "buy" rating in a research report on Wednesday, August 10th. HC Wainwright cut their price objective on shares of Clearside Biomedical from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday, August 10th. Finally, TheStreet lowered shares of Clearside Biomedical from a "c" rating to a "d+" rating in a research note on Wednesday, May 11th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $8.00.